Fortrea Holdings Inc.·Healthcare

Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcript

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.

Strong first-quarter performance reinforces confidence in FY 2026 guidance Book-to-bill of 1.15x is third consecutive quarter above 1.1x

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Healthcare
Biotechnology
15,000
2023-06-20
1.91